REPL crashed -32.1% during regular trading on Tuesday after FDA briefing documents cast serious doubt on the efficacy of its lead skin cancer drug candidate RP1 (vusolimogene oderparepvec). The FDA reviewers stated the single-arm IGNYTE trial design makes it impossible to determine whether RP1 contributed any meaningful benefit beyond Bristol Myers Squibb's Opdivo alone, calling the overall survival data "not interpretable."

ABVX shares surged approximately 30.1% over the last 30 days, climbing from $97.50 on June 26 to $126.86 as of July 27, driven by positive Phase 3 trial data and a landmark $920 million public offering. The stock's rapid recovery followed the release of ABTECT Maintenance Part 2 results on June 29, which alleviated earlier cancer-related safety concerns that had triggered a sharp selloff in early June.

SLS is trading at $10.69 during Monday's regular session, falling -5.57% from Friday's close of $11.32, reversing a +1% premarket gain. The stock hit an intraday low of $9.60 before a partial bounce, with volume exceeding 7 million shares amid a 20% intraday swing range.

MPLT plummeted -67.10% to $12.03 during regular trading Monday after reporting mixed Phase 2 ZEPHYR trial results for schizophrenia drug candidate ML-007C-MA. The selloff began in premarket (shares were indicated down -56%) and intensified through the session as investors digested the data.

REPL is trading at $8.16 during Monday's regular session, plunging -15.88% from Friday's close of $9.70, extending a multi-week selloff that has now erased over 25% in the past two weeks. The selloff follows a July 24 S-3/A filing registering up to 25.1 million shares held by Baker Brothers for potential resale, representing roughly 30% of the company's ~84 million shares outstanding.

CAPR plunged -66.24% to approximately $6.65, with the selloff beginning in premarket trading and deepening during the regular session. The FDA released briefing documents ahead of the July 29 advisory committee meeting, with staff reviewers raising substantial concerns about deramiocel's effectiveness for treating Duchenne muscular dystrophy-associated cardiomyopathy.

MPLT plummeted -66.63% to $12.20 as of late morning trading, after closing at $36.56 on Friday. The sell-off began in premarket, where shares had already fallen roughly -56% before the opening bell. The collapse was triggered by mixed Phase 2 ZEPHYR trial results for lead asset ML-007C-MA in schizophrenia. The twice-daily dose met the primary endpoint, but the once-daily dose failed to achieve statistical significance.

LEGN plunged -13.41% during Monday's regular session, falling to $19.24 from Friday's close of $22.22, extending a multi-week selloff that has erased roughly -36% of value since early July. The primary catalyst is the abrupt resignation of CEO Ying Huang, effective July 24, announced before Monday's open. Alan Bash, President of the CARVYKTI Business Unit, steps in as interim CEO while a permanent successor search begins.

ZVRA plummeted approximately -22.76% during Friday's regular session, extending a ~30% pre-market collapse that marks its steepest single-day decline since January 2021. The sell-off was triggered by the EMA's CHMP adopting a negative opinion on arimoclomol (Miplyffa), Zevra's lead therapy for Niemann-Pick disease type C, effectively blocking European market access.

IMMX dropped -13.27% during Monday's regular session after STAT News revealed its CMO "Richard Graydon" was actually Ronald Fischer, a fugitive convicted of sexual assault who spent 20 years evading authorities. The company disclosed Graydon's termination in a July 17 SEC filing but omitted the fugitive connection, stating his departure was "for reasons unrelated to his activities at the Company."

PVLA plunged -19.21% during Monday's regular trading session, tumbling from Friday's close of $157.24 to approximately $127.04, erasing much of last week's gains. The selloff represents a classic "sell-the-news" profit-taking event after shares recently surged to a 52-week high of $161.38, fueled by FDA granting a rolling review for the company's QTORIN rapamycin NDA submission.

Ascendis Pharma (ASND) shares climbed approximately 12.37% over the past 30 days, rising from $231.20 on June 16 to $259.80 on July 16, 2026. Inclusion in multiple Russell indexes — including the Russell 1000 and Russell MidCap — triggered a sharp single-day surge of roughly 10% on June 25, accompanied by the stock's highest trading volume in months.

Insmed shares gained approximately 9% over the 30-day period through mid-July 2026, reflecting growing commercial traction for newly launched Brinsupri in non-cystic fibrosis bronchiectasis (NCFB). The stock remains well below its 52-week high of $212.75, trading near $107, as the company works to scale its respiratory franchise and narrow operating losses.

Moderna shares have surged approximately 124% year to date through mid-July 2026, dramatically outperforming the broader biotech sector, while the 30-day net change remains a modest +2.2% following a sharp pullback from recent highs. The stock experienced a volatile short squeeze in late June, spiking from around $60 to an intra-quarter high above $85 before retracing to the low $60s as momentum cooled.

Revolution Medicines (RVMD) surged approximately 14% over the last 30 days, climbing from $156.58 on June 16 to $179.18 by July 16, 2026, driven by sustained momentum from landmark Phase 3 pancreatic cancer data. The broader quarterly trend underscores a powerful rally of roughly 20%, with shares advancing from around $149 in mid-April as the company's daraxonrasib program continued to deliver clinical and regulatory catalysts.

FTH shares collapsed -18.33% during regular trading to $25.70, extending yesterday's -4.98% drop and marking a brutal two-day selloff from the $35+ range. The crash follows a parabolic speculative run-up that propelled shares from ~$13 in mid-June to a 52-week high of $37.90 on July 13, fueled by the company's rebranding to Faeth Therapeutics.

ABSI shares are down -16.19% in regular trading on Thursday, extending a steep multi-day selloff that has now erased roughly 29% of the stock's value in just over a week. The decline is primarily driven by aggressive profit-taking after a massive +233% year-to-date rally through early July, with the stock retreating from its $12.06 52-week high as momentum traders and short-term investors lock in gains.

ATAI surged approximately +31.72% to $7.06 after Eli Lilly confirmed it will acquire the psychedelic drug developer in a deal valued at up to $3.8 billion. The rally was ignited in premarket trading following a Wednesday evening Bloomberg report that Lilly was in advanced buyout talks, with the official announcement confirming terms Thursday morning.

JNJ delivered strong Q2 2026 results with $25.3 billion in sales and raised full-year guidance, supporting steady performance in a diversified healthcare model. MRNA trades at approximately $68 with significant year-to-date gains exceeding 130%, though it faces expected revenue declines ahead of its July 31 earnings report.

Moderna shares surged approximately 55% over the past 30 days, driven by a unanimous FDA advisory committee vote backing its mRNA-based seasonal flu vaccine and a transformative Science Day presentation. The FDA's Vaccines and Related Biological Products Advisory Committee voted 9-0 that the benefits of mFLUSIVA (mRNA-1010) outweigh its risks for adults aged 50 and older, with a final regulatory decision expected by August 5, 2026.